Literature DB >> 17906618

The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

Hélène Plun-Favreau1, Kristina Klupsch, Nicoleta Moisoi, Sonia Gandhi, Svend Kjaer, David Frith, Kirsten Harvey, Emma Deas, Robert J Harvey, Neil McDonald, Nicholas W Wood, L Miguel Martins, Julian Downward.   

Abstract

In mice, targeted deletion of the serine protease HtrA2 (also known as Omi) causes mitochondrial dysfunction leading to a neurodegenerative disorder with parkinsonian features. In humans, point mutations in HtrA2 are a susceptibility factor for Parkinson's disease (PARK13 locus). Mutations in PINK1, a putative mitochondrial protein kinase, are associated with the PARK6 autosomal recessive locus for susceptibility to early-onset Parkinson's disease. Here we determine that HtrA2 interacts with PINK1 and that both are components of the same stress-sensing pathway. HtrA2 is phosphorylated on activation of the p38 pathway, occurring in a PINK1-dependent manner at a residue adjacent to a position found mutated in patients with Parkinson's disease. HtrA2 phosphorylation is decreased in brains of patients with Parkinson's disease carrying mutations in PINK1. We suggest that PINK1-dependent phosphorylation of HtrA2 might modulate its proteolytic activity, thereby contributing to an increased resistance of cells to mitochondrial stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906618     DOI: 10.1038/ncb1644

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  203 in total

1.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.

Authors:  Matthew W Bishop; Subhojit Chakraborty; Gillian A C Matthews; Antonios Dougalis; Nicholas W Wood; Richard Festenstein; Mark A Ungless
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

2.  Pink1 kinase and its membrane potential (Deltaψ)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode.

Authors:  Dorothea Becker; Judith Richter; Maja A Tocilescu; Serge Przedborski; Wolfgang Voos
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 3.  Non-apoptotic functions of apoptosis-regulatory proteins.

Authors:  Lorenzo Galluzzi; Oliver Kepp; Christina Trojel-Hansen; Guido Kroemer
Journal:  EMBO Rep       Date:  2012-04-02       Impact factor: 8.807

4.  PINK1- and Parkin-mediated mitophagy at a glance.

Authors:  Seok Min Jin; Richard J Youle
Journal:  J Cell Sci       Date:  2012-02-15       Impact factor: 5.285

Review 5.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 6.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

Review 7.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 8.  Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.

Authors:  Andrew B Knott; Ella Bossy-Wetzel
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease.

Authors:  Georgia S Gaki; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2014-02-13       Impact factor: 3.843

Review 10.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.